Recursion Pharmaceuticals Future Growth
Future criteria checks 2/6
Recursion Pharmaceuticals's earnings are forecast to decline at 3.9% per annum while its annual revenue is expected to grow at 20.9% per year. EPS is expected to grow by 2% per annum. Return on equity is forecast to be -177.5% in 3 years.
Key information
-3.9%
Earnings growth rate
2.0%
EPS growth rate
Biotechs earnings growth | 27.3% |
Revenue growth rate | 20.9% |
Future return on equity | -177.5% |
Analyst coverage | Good |
Last updated | 22 Jan 2025 |
Recent future growth updates
Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 12Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 12Recent updates
Recursion: Investors Will Need To Be Patient
Jan 10Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Dec 25Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245
Dec 09Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline
Nov 20Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week
Nov 10Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk
Nov 08Recursion: AI Is Only As Good As The Data
Sep 11Recursion: Path Forward For REC-994 Remains Despite Mixed Response
Sep 04Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 12Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts
Aug 01Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery
Jun 24Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must
Jun 14Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%
May 22Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 12Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate
Apr 10Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)
Mar 20Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely
Jan 31Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress
Jan 12Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues
Dec 09Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 103 | -347 | -221 | -205 | 5 |
12/31/2025 | 84 | -459 | -365 | -351 | 9 |
12/31/2024 | 68 | -418 | -311 | -298 | 9 |
9/30/2024 | 65 | -378 | -336 | -318 | N/A |
6/30/2024 | 50 | -375 | -346 | -332 | N/A |
3/31/2024 | 46 | -354 | -331 | -317 | N/A |
12/31/2023 | 45 | -328 | -300 | -288 | N/A |
9/30/2023 | 47 | -293 | -277 | -258 | N/A |
6/30/2023 | 50 | -260 | -266 | -240 | N/A |
3/31/2023 | 47 | -249 | -273 | -234 | N/A |
12/31/2022 | 40 | -239 | -121 | -84 | N/A |
9/30/2022 | 29 | -247 | -134 | -100 | N/A |
6/30/2022 | 18 | -234 | -113 | -78 | N/A |
3/31/2022 | 13 | -212 | -75 | -50 | N/A |
12/31/2021 | 10 | -186 | -198 | -159 | N/A |
9/30/2021 | 10 | -147 | -129 | -89 | N/A |
6/30/2021 | 9 | -124 | -106 | -75 | N/A |
3/31/2021 | 6 | -99 | -84 | -58 | N/A |
12/31/2020 | 4 | -87 | -52 | -45 | N/A |
12/31/2019 | 2 | -62 | -61 | -57 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RXRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RXRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RXRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RXRX's revenue (20.9% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: RXRX's revenue (20.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RXRX is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/02 02:08 |
End of Day Share Price | 2025/01/31 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Recursion Pharmaceuticals, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Gal Munda | Berenberg |
Gaurav Goparaju | Berenberg |
Alec Stranahan | BofA Global Research |